Ligand Pharmaceuticals Inc(LGND) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 4:54 AM ET (Korea 9/11 17:54)
Full metrics table
| Index | RUT | P/E | 30.92 | EPS (ttm) | 9.35 | Insider Own | 2.46% | Shs Outstand | 19.9M | Perf Week | 0.81% |
| Market Cap | 5.77B | Forward P/E | 23.88 | EPS next Y | 30.04% | Insider Trans | -16.39% | Shs Float | 19.4M | Perf Month | 0.17% |
| Enterprise Value | 5.54B | PEG | 1.12 | EPS next Q | 2.3 | Inst Own | 114.61% | Short Float | 12.59% | Perf Quarter | 16.52% |
| Income | 0.20B | P/S | 19.85 | EPS this Y | 14.58% | Inst Trans | 9.63% | Short Ratio | 6.83 | Perf Half Y | 30.74% |
| Sales | 0.29B | P/B | 5.96 | EPS next 5Y | 21.39% | ROA | 12.58% | Short Interest | 2.45M | Perf YTD | 52.99% |
| Book/sh | 48.57 | P/C | 4.25 | EPS past 3/5Y | - | ROE | 21.96% | 52W High | -11.44% ($326.63) | Perf Year | 74.28% |
| Cash/sh | 68.11 | P/FCF | 43.85 | Sales past 3/5Y | 10.96% 7.54% | ROIC | 9.4% | 52W Low | 78.75% ($161.82) | Perf 3Y | 358.76% |
| Dividend Est. | - | EV/EBITDA | 41.23 | EPS Y/Y TTM | 350.86% | Gross Margin | 84.28% | Volatility(W/M) | 2.74% 2.97% | Perf 5Y | 227.6% |
| Dividend TTM | - | EV/Sales | 19.07 | Sales Y/Y TTM | 54.89% | Oper. Margin | 34.45% | ATR (14) | 9.02 | Perf 10Y | 304.49% |
| Dividend Ex-Date | 2010/7/2 | Quick Ratio | 30.96 | EPS Q/Q | 813.4% | Profit Margin | 67.88% | RSI (14) | 50.84 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 31.18 | Sales Q/Q | 33.73% | SMA20 | 0.81% ($286.93) | Beta | 1.18 | Target Price | $352.4 |
| Payout | - | Debt/Eq | 1.17 | Earnings | 2026/8/6 | SMA50 | -2.34% ($296.18) | Rel Volume | 0.41 | Prev Close | $288.05 |
| Employees | 47 | LT Debt/Eq | 1.17 | EPS/Sales Surpr. | 17.92% 3.9% | SMA200 | 23.79% ($233.66) | Avg Volume(3M) | 0.36M | Price | $289.25 |
| IPO | 1992/11/18 | Option/Short | Yes/Yes | Trades | 5186 | Volume | 146,044 | Change | 0.42% |
Company
LGND is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 A biopharmaceutical royalty company built on a pharmaceutical royalty and formulation technology platform. Rather than selling its own drugs directly, its core model is an asset-light approach that provides technology and capital to other pharmaceutical companies for their new drug development and commercialization, in return for royalties. It holds multiple royalty assets along with formulation technology platforms such as Captisol.
Over the past 1 year, on the higher side
11% below its 1-year high.
LGND makes money exceptionally well
34.45% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +14.6% this year.
Tap to view numbers
The price looks about right
Trading at 30.9 times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +358.8% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 114.6%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
HELX 0.05%
PJP 0.04%
PSCH 0.02%
ALIL 0.02%
XPH 0.02%It ranks #4 in the industry
Based on market cap of $6B.
LGND $6B PER 30.9
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is LGND?
LGND belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of LGND?
The market cap of LGND is approximately $5.8B, ranking 1,276 within its sector.
What is the P/E ratio of LGND?
LGND has a P/E ratio of approximately 30.9x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for LGND?
LGND has recorded a 52-week high of $326.63 and a low of $161.82.
